This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agnico Eagle (AEM) Bumps Up Stake in Maple Gold Mines to 19.9%
by Zacks Equity Research
Agnico Eagle (AEM) raises its stake in Maple Gold Mines Ltd to 19.9%. It enters into a deal under which Maple will obtain a 100% interest in the Douay and Joutel Gold Projects.
Mosaic's (MOS) April and May Sales Volume and Revenues Down
by Zacks Equity Research
Mosaic (MOS) posts significant declines in sales volume and revenues across potash, phosphate and Mosaic Fertilizantes in April and May 2024.
Fission Uranium (FCUUF) Agrees to be Acquired by Paladin Energy
by Zacks Equity Research
Fission Uranium (FCUUF) is set to be acquired by Paladin Energy. This deal will create a leading uranium producer with a robust portfolio of exploration, development and production assets.
Should You Invest in the iShares U.S. Basic Materials ETF (IYM)?
by Zacks Equity Research
Sector ETF report for IYM
Air Liquide (AIQUY) to Invest Up to $850M in Low-Carbon Oxygen
by Zacks Equity Research
The agreement allows Air Liquide (AIQUY) to capitalize on its existing pipeline infrastructure to promote the development of low-carbon hydrogen.
BASF (BASFY) and Enerflex Collaborate for CCUS Applications
by Zacks Equity Research
Per the deal, Enerflex's engineering, manufacturing and integration experience in gas processing and compression systems will be combined with BASF's (BASFY) OASE blue technology for CO2 capture.
GE HealthCare (GEHC) Boosts Interventional Radiology Capabilities
by Zacks Equity Research
GE HealthCare's (GEHC) latest successful first installation and clinical cases using the OmnifyXR are likely to improve clinical and operational outcomes for both patients and clinicians.
Accuray (ARAY), TrueNorth Unite to Aid Radiation Departments
by Zacks Equity Research
Accuray (ARAY) announces an agreement with TrueNorth to provide radiation oncology departments with third-party support designed to improve their department's capabilities.
BASF (BASFY)-Encina Announce Long-Term Recycled Benzene Deal
by Zacks Equity Research
BASF (BASFY) and Encina ink a long-term agreement to supply chemically recycled circular benzene, advancing sustainable sourcing and circular economy goals.
Bunge Global (BG) to Sell Its 50% Stake in BP Bunge Bioenergia
by Zacks Equity Research
Bunge Global (BG) to focus on core businesses with the sale of its shares in the BP Bunge Bioenergia joint venture.
B2Gold (BTG) Sells 10% Stake in Calibre Mining for C$139M
by Zacks Equity Research
B2Gold (BTG) sells 79 million common shares of Calibre Mining as part of its capital allocation strategy.
Air Liquide (AIQUY) & Dunkerque Project Gets EU's Support
by Zacks Equity Research
The D'Artagnan project will involve an Air Liquide (AIQUY) pipeline carrying CO2 from capture sites, as well as a terminal in the port of Dunkirk for liquefying and loading CO2 onto ships.
McKesson (MCK) Reaches 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
DexCom's (DXCM) G6 CGM System Combines With AID in Netherlands
by Zacks Equity Research
DexCom (DXCM) announces expansion of its AID partnership in the Netherlands to offer an easier diabetes management experience.
Dow (DOW) Acquires Circulus to Boost Circular Economy Efforts
by Zacks Equity Research
Dow (DOW) is acquiring Circulus to enhance its materials science and film recycling capabilities, expanding its circular product offerings.
DuPont (DD) & Desun Launch Flexible Solar Panels in Germany
by Zacks Equity Research
DuPont (DD) Tedlar frontsheets have a unique mix of mechanical durability, abrasion resistance, outdoor stability and high light transmittance.
Veeva's (VEEV) Vault EDC to Boost Vita Global's Data Management
by Zacks Equity Research
Veeva's (VEEV) Vault EDC is likely to improve Vita Global's clinical data management processes.
McKesson (MCK) Introduces FDA-Approved Prostate Cancer Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients improved treatment options for prostate cancer.
Venus Concept's (VERO) Latest Supply Deal to Aid its Business
by Zacks Equity Research
Venus Concept (VERO) announces an exclusive strategic supply arrangement with Skin Laundry Holdings, Inc.
B2Gold (BTG) Provides Upbeat Assessment Results for Gramolate
by Zacks Equity Research
B2Gold (BTG) announces the latest preliminary economic assessment results for the Gramalote project indicating an average yearly production of 185,000 ounces of gold over a 12.5-year life.
Universal Stainless (USAP) Rallies 78% in 6 Months: Here's Why
by Zacks Equity Research
Solid first-quarter performance on the back of the strength in aerospace contributes to the rally in Universal Stainless' (USAP) shares.
BrainsWay (BWAY) Inks Distribution Agreement to Expand Foothold
by Zacks Equity Research
BrainsWay's (BWAY) latest exclusive multi-year distribution agreement is likely to provide improved patient care in Canada.
Green Plains (GPRE) Updates on Nebraska Carbon Capture Project
by Zacks Equity Research
Green Plains (GPRE) enters into construction agreements and funding arrangements to facilitate the ordering of carbon sequestration equipment.
Lantheus (LNTH) Gains 33.3% YTD: What's Driving the Stock?
by Zacks Equity Research
Lantheus' (LNTH) focus on pipeline development raises optimism about the stock.
Energy Fuels (UUUU) Appoints Director to Grow REE Business
by Zacks Equity Research
Energy Fuels (UUUU) appoints Debra Bennethum as the director to grow its rare earth business. It also achieves the commercial production of separated REE at its White Mesa Mill.